Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 7/20 | 0.79 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 3/20 | 0.41 |
| ▸ | VCP | P55072 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | KMO | O15229 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9893818 | 0.92 | MDM2 (0.66) | MDM2NOTUMGRM5 | |
| SCHEMBL1437096 | 0.91 | MDM2 (0.79) | MDM2NOTUMGRM5RIPK1KMO | |
| SCHEMBL9893678 | 0.89 | MDM2 (0.62) | MDM2GRM5 | |
| SCHEMBL1443240 | 0.88 | MDM2 (1.00) | MDM2NOTUMPIN1PKMRIPK1 | |
| SCHEMBL1438150 | 0.87 | MDM2 (0.88) | MDM2NOTUMPIN1PKMRIPK1 | |
| SCHEMBL27879077 | 0.87 | MDM2 (0.88) | MDM2NOTUMPIN1PKMRIPK1 | |
| SCHEMBL9893709 | 0.86 | MDM2 (0.80) | MDM2PIN1GRM5PKMSORT1 | |
| SCHEMBL1437176 | 0.85 | MDM2 (0.90) | MDM2NOTUMPIN1RIPK1KMO | |
| SCHEMBL27879080 | 0.84 | MDM2 (0.82) | MDM2NOTUMPIN1PKMRIPK1 | |
| SCHEMBL1438330 | 0.83 | MDM2 (0.67) | MDM2NOTUMGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102574785-A | Tetra-substituted heteroaryl compounds and their use as MDM2 and/or MDM4 modulators | NOVARTIS AG | 2012-07-11 | — | — | CN | disclosed |
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | MDM2 2/4885NOTUM 4675/4885PIN1 844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.